SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-011572
Filing Date
2021-08-13
Accepted
2021-08-13 07:31:03
Documents
64
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20210630x10q.htm   iXBRL 10-Q 1809163
2 EX-31.1 akro-20210630xex31d1.htm EX-31.1 11497
3 EX-31.2 akro-20210630xex31d2.htm EX-31.2 11638
4 EX-32.1 akro-20210630xex32d1.htm EX-32.1 10850
  Complete submission text file 0001558370-21-011572.txt   6340851

Data Files

Seq Description Document Type Size
5 EX-101.SCH akro-20210630.xsd EX-101.SCH 42442
6 EX-101.CAL akro-20210630_cal.xml EX-101.CAL 36641
7 EX-101.DEF akro-20210630_def.xml EX-101.DEF 106748
8 EX-101.LAB akro-20210630_lab.xml EX-101.LAB 401456
9 EX-101.PRE akro-20210630_pre.xml EX-101.PRE 281302
10 EXTRACTED XBRL INSTANCE DOCUMENT akro-20210630x10q_htm.xml XML 1060829
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 211169739
SIC: 2834 Pharmaceutical Preparations